Market Place
Sourcing Support
APRINOIA Gets FDA Fast Track For APN-1607 In Supranuclear Palsy Diagnosis
21 May 2024 //
GLOBENEWSWIRE
APRINOIA`s APN-1607 Granted FDA Fast Track For PSP Diagnosis
20 May 2024 //
GLOBENEWSWIRE
APRINOIA Therapeutics Announces Strategic Investment From The ADDF
11 Sep 2023 //
GLOBENEWSWIRE
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as CEO
28 Aug 2023 //
GLOBENEWSWIRE
Ex-US Commerce Secretary Wilbur Ross pairs his SPAC with Alzheimer`s biotech
18 Jan 2023 //
ENDPTS
APRINOIA Tx Bags FDA clearance to initiate APNmAb005 Phase 1 clinical trial
11 Apr 2022 //
PRNEWSWIRE
Insilico & APRINOIA to discover next-gen compounds for neurodegenerative
31 Dec 2020 //
BIOSPECTRUMASIA
Insilico and APRINOIA to discover next-gen compounds for neurodegenerative
29 Dec 2020 //
BIOSPECTRUMASIA
APRINOIA announces NMPA approval to initiate Ph 3 clinical trial
28 Oct 2020 //
BIOSPECTRUMASIA
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial
28 Oct 2020 //
PRNEWSWIRE
Aprinoia starts Ph 2 study of PET imaging tracer for Alzheimer`s
21 Nov 2019 //
BIOSPECTRUM ASIA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.